CAM
CLRB icon

Cozad Asset Management’s Cellectar Biosciences CLRB Stock Holding History

Cozad Asset Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-187
Closed -$23K – 351
2022
Q2 		$23K Hold
187
– – ﹤0.01% 347
2022
Q1 		$39K Hold
187
– – 0.01% 350
2021
Q4 		$37K Buy
187
+17
+10% +$4.09K 0.01% 351
2021
Q3 		$47K Buy
170
+67
+65% +$20.4K 0.01% 346
2021
Q2 		$37K Buy
103
+66
+178% +$28.6K 0.01% 347
2021
Q1 		$18K Hold
37
– – ﹤0.01% 350
2020
Q4 		$23K Buy
+37
New +$17K ﹤0.01% 327

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cozad Asset Management's CLRB Position: Q3 2022 in Review

Cozad Asset Management sold out of Cellectar Biosciences (CLRB) in Q3 2022, closing a stake of 187 shares — an estimated $23K sold.

Cozad Asset Management first reported a position in CLRB in Q4 2020 and held it in 7 quarters. The position peaked at $47K in Q3 2021. 20 funds tracked by Wall St. Rank hold CLRB as of Q3 2022.

  • Cozad Asset Management reported no remaining Cellectar Biosciences position as of Q3 2022 after selling out during the quarter.
  • Cozad Asset Management sold 187 Cellectar Biosciences shares in Q3 2022, an estimated $23K.
  • Cozad Asset Management first reported a position in Cellectar Biosciences in Q4 2020 and held it in 7 quarters.
  • Cozad Asset Management's Cellectar Biosciences position peaked at $47K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2022.

Based on Cozad Asset Management's 13F filing for Q3 2022, filed 7 Nov 2022.